| Symbol | EVAX |
|---|---|
| Name | EVAXION A/S |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | DR. NEERGAARDS VEJ 5F, HOERSHOLM, DK-2970, Denmark |
| Telephone | +45 53531850 |
| Fax | — |
| — | |
| Website | https://www.evaxion-biotech.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001828253 |
| Description | Evaxion A/S want to challenge and improve todays standardized treatments with the help of our AI-Immunology platform. In the field of oncology, we create truly personalized therapies where one size fits one, and only one. Within infectious diseases, we use the technology to design next-generation vaccines to address unmet medical needs. Additional info from NASDAQ: |
Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026
Read moreEvaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1
Read moreEvaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop
Read moreEvaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia
Read moreEvaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress
Read moreEvaxion announces business update and first quarter 2026 financial results
Read moreEvaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer
Read moreNew Form 3 - Evaxion A/S <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 0001104659-26-048722 <b>Size:</b> 10 KB
Read more